Edited By: Chiara Romagnani (Chair of the Executive Committee)
Overview
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.
Highlights
Call for Papers
European Journal of Immunology invites article submissions for several special issue on various topics in basic, clinical and translational immunology.
Further to our commitment for supporting young immunologists, EJI is highlighting the work of first-time first authors as well as first-time corresponding authors. Join us and celebrate the outstanding work of early career immunologists around the globe!
Now online:
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Click here to access EJI´s 50th Anniversary Review Collection
Click here to access EJI´s COVID-19 articles
Boost Vaccination and Monoclonal Antibodies neutralize the SARS-CoV-2 Omicron Variant
Schulz, Jäck and colleagues
Intranasal vaccination with ChAdOx1-S adenoviral vector promotes superior mucosal immunity compared to the intramuscular route
Brdovčak, Krmpotić and colleagues
Articles
Czech Young Immunologists: Bound by Science, United in Purpose
- 28 September 2023
Cryopreservation of mouse thymus depletes thymocytes but supports immune reconstitution on transplantation
- 26 September 2023
Young EFIS: Three years of progress ‐ Reflecting on achievements and embracing new horizons
- 26 September 2023
Myeloid‐derive suppressor cells in the therapy of autoimmune diseases
- 25 September 2023
Graphical Abstract
The role of myeloid-derived suppressor cells (MDSCs) in autoimmunity is unclear. Reviewed studies suggest that MDSCs can be pathogenic or beneficial, depending on the disease stage and underlying mechanisms. The therapeutic potential of MDSCs could be harnessed in well-controlled cell therapy or direct expansion and activation of MDSCs in vivo.
SHIP1 and its role for innate immune regulation – novel targets for immunotherapy
- 24 September 2023
The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.
CD69: from activation marker to metabolic gatekeeper
- 946-953
- 5 May 2017
Graphical Abstract
CD69 associates to LAT1 and controls its plasma membrane expression and amino acid transporter activity in T lymphocytes.
Nanoparticles target distinct dendritic cell populations according to their size
- 1404-1413
- 18 April 2008
The who's who of T-cell differentiation: Human memory T-cell subsets
- 2797-2809
- 30 October 2013
IL‐6: Regulator of Treg/Th17 balance
- European Journal of Immunology
- 1830-1835
- 25 June 2010
CD69: from activation marker to metabolic gatekeeper
- European Journal of Immunology
- 946-953
- 5 May 2017
Graphical Abstract
CD69 associates to LAT1 and controls its plasma membrane expression and amino acid transporter activity in T lymphocytes.
Recent issues
Latest news
Sign up for email alerts
Tools
An official journal of the European Federation of Immunological Societies
